These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 33482809)

  • 1. Cofilin-1, LIMK1 and SSH1 are differentially expressed in locally advanced colorectal cancer and according to consensus molecular subtypes.
    Sousa-Squiavinato ACM; Vasconcelos RI; Gehren AS; Fernandes PV; de Oliveira IM; Boroni M; Morgado-Díaz JA
    Cancer Cell Int; 2021 Jan; 21(1):69. PubMed ID: 33482809
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LIMK/cofilin pathway and Slingshot are implicated in human colorectal cancer progression and chemoresistance.
    Aggelou H; Chadla P; Nikou S; Karteri S; Maroulis I; Kalofonos HP; Papadaki H; Bravou V
    Virchows Arch; 2018 May; 472(5):727-737. PubMed ID: 29352327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SSH3 facilitates colorectal cancer cell invasion and metastasis by affecting signaling cascades involving LIMK1/Rac1.
    Hu YH; Lu YX; Zhang ZY; Zhang JM; Zhang WJ; Zheng L; Lin WH; Zhang W; Li XN
    Am J Cancer Res; 2019; 9(5):1061-1073. PubMed ID: 31218112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of SSH1 in colorectal cancer prognosis and tumor progression.
    Song X; Xie D; Xia X; Tan F; Pei Q; Li Y; Zhou Z; Zhou Y; Li C; Wang K; Pei H
    J Gastroenterol Hepatol; 2020 Jul; 35(7):1180-1188. PubMed ID: 32020663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LIMK1: A promising prognostic and immune infiltration indicator in colorectal cancer.
    Liu X; Song Q; Wang D; Liu Y; Zhang Z; Fu W
    Oncol Lett; 2022 Jul; 24(1):234. PubMed ID: 35720504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The correlation between immune subtypes and consensus molecular subtypes in colorectal cancer identifies novel tumour microenvironment profiles, with prognostic and therapeutic implications.
    Soldevilla B; Carretero-Puche C; Gomez-Lopez G; Al-Shahrour F; Riesco MC; Gil-Calderon B; Alvarez-Vallina L; Espinosa-Olarte P; Gomez-Esteves G; Rubio-Cuesta B; Sarmentero J; La Salvia A; Garcia-Carbonero R
    Eur J Cancer; 2019 Dec; 123():118-129. PubMed ID: 31678770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phenotypic subtypes predict outcomes in colorectal cancer.
    Kasurinen J; Beilmann-Lehtonen I; Kaprio T; Hagström J; Haglund C; Böckelman C
    Acta Oncol; 2023 Mar; 62(3):245-252. PubMed ID: 36867078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interconnectivity between molecular subtypes and tumor stage in colorectal cancer.
    Coebergh van den Braak RRJ; Ten Hoorn S; Sieuwerts AM; Tuynman JB; Smid M; Wilting SM; Martens JWM; Punt CJA; Foekens JA; Medema JP; IJzermans JNM; Vermeulen L
    BMC Cancer; 2020 Sep; 20(1):850. PubMed ID: 32887573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Upregulation of LIMK1 Is Correlated With Poor Prognosis and Immune Infiltrates in Lung Adenocarcinoma.
    Lu G; Zhou Y; Zhang C; Zhang Y
    Front Genet; 2021; 12():671585. PubMed ID: 34149814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroRNA-384 inhibits the progression of esophageal squamous cell carcinoma through blockade of the LIMK1/cofilin signaling pathway by binding to LIMK1.
    Yu HX; Wang XL; Zhang LN; Zhang J; Zhao W
    Biomed Pharmacother; 2019 Jan; 109():751-761. PubMed ID: 30551528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Value of Consensus Molecular Subtypes in Colorectal Cancer: A Systematic Review and Meta-Analysis.
    Ten Hoorn S; de Back TR; Sommeijer DW; Vermeulen L
    J Natl Cancer Inst; 2022 Apr; 114(4):503-516. PubMed ID: 34077519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigation of colorectal cancer in accordance with consensus molecular subtype classification.
    Sawayama H; Miyamoto Y; Ogawa K; Yoshida N; Baba H
    Ann Gastroenterol Surg; 2020 Sep; 4(5):528-539. PubMed ID: 33005848
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LIM kinase 1 interacts with myosin-9 and alpha-actinin-4 and promotes colorectal cancer progression.
    Liao Q; Li R; Zhou R; Pan Z; Xu L; Ding Y; Zhao L
    Br J Cancer; 2017 Aug; 117(4):563-571. PubMed ID: 28664914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Classification of colorectal cancer consensus molecular subtypes using attention-based multi-instance learning network on whole-slide images.
    Xu H; Wu A; Ren H; Yu C; Liu G; Liu L
    Acta Histochem; 2023 Aug; 125(6):152057. PubMed ID: 37300984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Classification of patients with metastatic colorectal cancer into consensus molecular subtypes into real-world: A pilot study.
    González-Montero J; Burotto M; Valenzuela G; Mateluna D; Buen-Abad F; Toro J; Barajas O; Marcelain K
    World J Clin Oncol; 2023 Oct; 14(10):409-419. PubMed ID: 37970108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinical significance of CCBE1 expression in human colorectal cancer.
    Zhao YR; Liu H; Xiao LM; Jin CG; Zhang ZP; Yang CG
    Cancer Manag Res; 2018; 10():6581-6590. PubMed ID: 30555263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased expression of formin-like 3 contributes to metastasis and poor prognosis in colorectal carcinoma.
    Zeng YF; Xiao YS; Lu MZ; Luo XJ; Hu GZ; Deng KY; Wu XM; Xin HB
    Exp Mol Pathol; 2015 Apr; 98(2):260-7. PubMed ID: 25758200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prognostic impact of consensus molecular subtypes (CMS) and its predictive effects for bevacizumab benefit in metastatic colorectal cancer: molecular analysis of the AGITG MAX clinical trial.
    Mooi JK; Wirapati P; Asher R; Lee CK; Savas P; Price TJ; Townsend A; Hardingham J; Buchanan D; Williams D; Tejpar S; Mariadason JM; Tebbutt NC
    Ann Oncol; 2018 Nov; 29(11):2240-2246. PubMed ID: 30247524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Claudin gene expression profiles and clinical value in colorectal tumors classified according to their molecular subtype.
    Cherradi S; Martineau P; Gongora C; Del Rio M
    Cancer Manag Res; 2019; 11():1337-1348. PubMed ID: 30863148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High Expression of LTBP2 Contributes to Poor Prognosis in Colorectal Cancer Patients and Correlates with the Mesenchymal Colorectal Cancer Subtype.
    Huang Y; Wang G; Zhao C; Geng R; Zhang S; Wang W; Chen J; Liu H; Wang X
    Dis Markers; 2019; 2019():5231269. PubMed ID: 30956730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.